Early results from a phase II randomized trial testing stereotactic body radiation therapy in patients with oligometastatic castration resistant prostate cancer undergoing I line treatment with abiraterone acetate (ARTO trial-NCT03449719)

Early results from a phase II randomized trial testing stereotactic body radiation therapy in patients with oligometastatic castration resistant prostate cancer undergoing I line treatment with abiraterone acetate (ARTO trial-NCT03449719)

Bibliographic Details
Main Authors: G. Francolini, P. Garlatti, B. Detti, A. Bruni, G. Mantini, S. Pergolizzi, P. Borghetti, R.M. D’Angelillo, F. Alongi, B.A. Jereczek-Fossa, C. Franzese, A. Tagliagambe, V. Di Cataldo, M. Aquilano, M. Mariotti, V. Salvestrini, L. Ciccone, G. Stocchi, L. Livi
Format: Article
Language:English
Published: Elsevier 2020-11-01
Series:European Urology Open Science
Online Access:http://www.sciencedirect.com/science/article/pii/S2666168320362078

Internet

http://www.sciencedirect.com/science/article/pii/S2666168320362078

Similar Items